The Form 4 filing, an SEC report of insider share activity, was filed on Nov. 12, 2026. The sales took place on Nov. 10, two days earlier.
The report lists one insider, Jason Aryeh, a director of Ligand Pharmaceuticals (LGND). The company is listed in the healthcare sector and biotechnology industry.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-10 |
| Date of Latest Transaction | 2026-11-10 |
| Buy/Sell | sell |
| Transaction Count | 6 |
| Shares Transacted | 3,000 |
| Price | $320.05 |
| Total Transaction Value | $960,140.98 |
| Insider | |
| Ticker Symbol | LGND |
| Company | LIGAND PHARMACEUTICALS INC |
| Insider Name | Aryeh Jason |
| Insider Title | Director |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 105,476 |
| Position Size Change | 2.77% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported under transaction code S. The filing covers six transactions, all dated Nov. 10, 2026.
What was the average price of the transaction?
The average price across the six sales was $320.05 per share, rounded to the nearest cent. Prices for the individual sales were unavailable.
How did this transaction affect the insider's holdings?
The sales reduced Jason Aryeh's reported holdings by 3,000 shares, leaving 105,476 shares. Based on those figures, he held 108,476 shares before the sales. The shares sold made up 2.77% of that earlier balance.
What's the total transaction value?
The total value was $960,140.98 for the six reported sales.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement. Filing footnotes were unavailable for this report, so any further terms or explanations remain unknown.
For research purposes only; not investment advice.